Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 2/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.46 |
| ▸ | AVPR1A | P37288 | 10/20 | 0.39 |
| ▸ | HTR5A | P47898 | 2/20 | 0.39 |
| ▸ | OXTR | P30559 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | SNCA | P37840 | 1/20 | 0.36 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.34 |
| ▸ | TUBB | P07437 | 1/20 | 0.34 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.34 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.34 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.34 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.34 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.34 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.34 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.34 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.34 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.34 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29989621 | 1.00 | PDE3B (0.46) | PDE3BPDE3AAVPR1AHTR5AOXTR | |
| SCHEMBL21379004 | 0.83 | TSPO (0.35) | AVPR1AHTR5AOXTR | |
| SCHEMBL21396613 | 0.82 | AVPR1A (0.37) | AVPR1AOXTRCHRM1 | |
| SCHEMBL21379279 | 0.82 | TSPO (0.34) | AVPR1AHTR5AOXTRCHRM1 | |
| SCHEMBL29990044 | 0.82 | CHRM1 (0.34) | AVPR1AHTR5AOXTRCHRM1 | |
| SCHEMBL21379060 | 0.82 | CHRM1 (0.34) | AVPR1AHTR5AOXTRCHRM1 | |
| SCHEMBL29990699 | 0.82 | TSPO (0.34) | AVPR1AHTR5AOXTRCHRM1 | |
| SCHEMBL1496015 | 0.80 | TSPO (0.48) | AVPR1AHTR5AOXTR | |
| Hydrochloric Acid SCHEMBL25255088 | 0.79 | TSPO (0.47) | AVPR1AHTR5AOXTR | |
| SCHEMBL1495917 | 0.78 | TSPO (0.37) | AVPR1AHTR5AOXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034142-A1 | Therapeutic Compounds and Compositions for Treating Social Disorders and Substance Use Disorders | Kinoxis Therapeutics Pty Ltd (AU) | 2026-02-05 | — | — | US | disclosed |
| US-12458648-B2 | Therapeutic compounds and compositions for treating social disorders and substance use disorders | KINOXIS THERAPEUTICS PTY LTD. (AU) | 2025-11-04 | — | — | US | disclosed |
| EP-3551631-B9 | NON-PEPTIDE OXYTOCIN RECEPTOR AGONISTS | Kinoxis Therapeutics Pty Ltd (AU) | 2025-02-26 | — | — | EP | disclosed |
| EP-4494705-A2 | NON-PEPTIDE OXYTOCIN RECEPTOR AGONISTS | Kinoxis Therapeutics Pty Ltd (AU) | 2025-01-22 | — | — | EP | disclosed |
| EP-3551631-B1 | NON-PEPTIDE OXYTOCIN RECEPTOR AGONISTS | Kinoxis Therapeutics Pty Ltd (AU) | 2024-11-13 | — | — | EP | disclosed |
| US-20240245706-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS FOR TREATING SOCIAL DISORDERS AND SUBSTANCE USE DISORDERS | Kinoxis Therapeutics Pty Ltd (AU) | 2024-07-25 | — | — | US | disclosed |
| US-11890287-B2 | Therapeutic compounds and compositions for treating social disorders and substance use disorders | Kinoxis Therapeutics Pty Ltd (AU) | 2024-02-06 | — | — | US | disclosed |
| US-20230330103-A1 | NON-PEPTIDE OXYTOCIN RECEPTOR AGONISTS | Kinoxis Therapeutics Pty Ltd (AU) | 2023-10-19 | — | — | US | disclosed |
| US-20230330103-A1 | NON-PEPTIDE OXYTOCIN RECEPTOR AGONISTS | Kinoxis Therapeutics Pty Ltd (AU) | 2023-10-19 | — | — | US | disclosed |
| US-20230330103-A1 | NON-PEPTIDE OXYTOCIN RECEPTOR AGONISTS | Kinoxis Therapeutics Pty Ltd (AU) | 2023-10-19 | — | — | US | disclosed |
| US-20220362261-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS FOR TREATING SOCIAL DISORDERS AND SUBSTANCE USE DISORDERS | THE UNIVERSITY OF SYDNEY (AU) | 2022-11-17 | — | — | US | disclosed |
| US-11491165-B2 | Non-peptide oxytocin receptor agonists | Kinoxis Therapeutics Pty Ltd (AU) | 2022-11-08 | — | — | US | disclosed |
| EP-3328864-B1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS FOR TREATING SOCIAL DISORDERS AND SUBSTANCE USE DISORDERS | Kinoxis Therapeutics Pty Ltd (AU) | 2022-09-07 | — | — | EP | disclosed |
| US-11033555-B2 | Therapeutic compounds and compositions for treating social disorders and substance use disorders | Kinoxis Therapeutics Pty Ltd (AU) | 2021-06-15 | — | — | US | disclosed |
| US-11033555-B2 | Therapeutic compounds and compositions for treating social disorders and substance use disorders | Kinoxis Therapeutics Pty Ltd (AU) | 2021-06-15 | — | — | US | disclosed |
| EP-3551631-A1 | NON-PEPTIDE OXYTOCIN RECEPTOR AGONISTS | The University of Sydney (AU) | 2019-10-16 | — | — | EP | disclosed |
| US-20190290658-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS FOR TREATING SOCIAL DISORDERS AND SUBSTANCE USE DISORDERS | Kinoxis Therapeutics Pty Ltd (AU) | 2019-09-26 | — | — | US | disclosed |
| US-20190290658-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS FOR TREATING SOCIAL DISORDERS AND SUBSTANCE USE DISORDERS | Kinoxis Therapeutics Pty Ltd (AU) | 2019-09-26 | — | — | US | disclosed |
| WO-2018107216-A1 | NON-PEPTIDE OXYTOCIN RECEPTOR AGONISTS | THE UNIVERSITY OF SYDNEY (AU) | 2018-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240245706-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS FOR TREATING SOCIAL DISORDERS AND SUBSTANCE USE DISORDERS | SLC18A2, SLC6A3, CES2 | PDE3B 413/4885PDE3A 320/4885AVPR1A 555/4885 |
| US-12458648-B2 | Therapeutic compounds and compositions for treating social disorders and substance use disorders | SLC18A2, SLC6A3, CES2 | PDE3B 413/4885PDE3A 320/4885AVPR1A 555/4885 |
| US-11491165-B2 | Non-peptide oxytocin receptor agonists | OXTR, AVPR1B, AVPR1A | PDE3B 884/4885PDE3A 703/4885AVPR1A 3/4885 |
| US-11890287-B2 | Therapeutic compounds and compositions for treating social disorders and substance use disorders | SLC18A2, SLC6A3, CES2 | PDE3B 413/4885PDE3A 320/4885AVPR1A 555/4885 |
| US-20190290658-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS FOR TREATING SOCIAL DISORDERS AND SUBSTANCE USE DISORDERS | SLC18A2, SLC6A3, CES2 | PDE3B 399/4885PDE3A 312/4885AVPR1A 550/4885 |
| US-20230330103-A1 | NON-PEPTIDE OXYTOCIN RECEPTOR AGONISTS | OXTR, AVPR1B, AVPR1A | PDE3B 884/4885PDE3A 703/4885AVPR1A 3/4885 |
| US-11033555-B2 | Therapeutic compounds and compositions for treating social disorders and substance use disorders | SLC18A2, SLC6A3, CES2 | PDE3B 399/4885PDE3A 312/4885AVPR1A 550/4885 |
| US-20260034142-A1 | Therapeutic Compounds and Compositions for Treating Social Disorders and Substance Use Disorders | SLC6A3, SLC6A4, SLC6A1 | PDE3B 427/4885PDE3A 256/4885AVPR1A 412/4885 |
| US-20220362261-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS FOR TREATING SOCIAL DISORDERS AND SUBSTANCE USE DISORDERS | SLC18A2, SLC6A3, CES2 | PDE3B 413/4885PDE3A 320/4885AVPR1A 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.